Aloxi (palonosetron oral) / Helsinn, Otsuka, Roche, Eisai, Immedica 
Welcome,         Profile    Billing    Logout  
 3 Diseases   0 Trials   0 Trials   65 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Aloxi (palonosetron oral) / Helsinn, Otsuka, Roche, Eisai, Immedica
NCT05841849: Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

Not yet recruiting
4
1028
RoW
Aprepitant, Palonosetron, Fosaprepitant
Second Affiliated Hospital, School of Medicine, Zhejiang University
Breast Cancer, Chemotherapy-induced Nausea and Vomiting
07/28
07/29
PATROL-II, UMIN000038644: A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer

Recruiting
2
89
Japan
Aloxi (palonosetron oral) - Helsinn, Otsuka, Roche, Eisai, Immedica, aprepitant oral - Generic mfg., olanzapine - Generic mfg.
Hoshi University; Division of Applied Pharmaceutical, University of Shizuoka, School of Pharmaceutical Sciences
Breast cancer;Oncology
 
 
ACTRN12624000079549: PhaRmacogEnomiC medIcines optimiSatIon for peOple with caNcer – a multicentre teletrial enabled Interrupted Time Series trial (PRECISION-ITS): Pharmacogenomics primary study and discovery program

Not yet recruiting
N/A
1470
 
Peter MacCallum Cancer Centre , Peter MacCallum Cancer Centre , Department of Health and Aged care (Medical research future fund)
Cancer and other malignant neoplasms
 
 

Download Options